BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Report an Adverse Event

To report an adverse event/reaction and/or product complaint to BDSI, call 1-800-469-0261 and select option 1. Or email the information requested below to drugsafety@bdsi.com.

When choosing this option please have the following information ready:

  • Identifiable reporter
  • Identifiable patient (gender)
  • Adverse reaction and/or product complaint
  • Suspect lot number and/or dosing information
  • Callback number and/or email

To report an adverse event/reaction directly to FDA’s MedWatch program, call 1-800-FDA-1088 (1-800-332-1088) or go to www.fda.gov/Safety/MedWatch.

If you wish to be contacted by your local BDSI representative, call 1-800-469-0261 and select option 6.

BDSI routinely collects and analyzes safety information on our products, including reports from healthcare professionals and patients about Adverse Events and Product Complaints. We submit reports as appropriate to the U.S. Food and Drug Administration (FDA) which reviews these reports.

Recent BDSI News

April 20, 2021

RALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021

Read more
March 10, 2021

Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million , Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today

Read more
February 17, 2021

RALEIGH, N.C. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its fourth quarter and full

Read more
More news

Upcoming Events

BDSI First Quarter 2021 Financial Results Call and Webcast May 6, 2021 8:30 AM EDT

Stay Connected

Stay up to date on the latest news

Get started now
April 21, 2021BDSI $3.42/ - 0%
Data provided by Nasdaq. Minimum 15 minutes delayed.